Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address unmet medical needs in otolaryngology, announced that it will provide an update on its development program with AM-111 for the treatment of acute inner ear hearing loss on Thursday, January 4, 2018. Following the announcement, Auris Medical’s management team will host a live conference call and webcast at 8 am EST (2 pm CET), featuring Hinrich Staecker, MD, PhD, professor of otolaryngology at the University of Kansas Medical Center. Staecker trained at Albert Einstein College of Medicine and Massachusetts Eye and Ear Infirmary and has been in practice for over 25 years with a primary focus on neurotology and otology. His research activities are mainly dedicated to developing treatments for hearing loss. Staecker has published numerous articles and book chapters.
To participate in this conference call, dial 1-800-281-7973 (USA) or +1-646-828-8156 (International), and enter passcode 2284504. A live webcast of the conference call can be accessed in the Investor Relations section of the Auris Medical website at www.aurismedical.com. A replay will be available approximately two hours following the live call.
Source: Auris Medical
